Susceptibility to quinupristin-dalfopristin and linezolid in 839 clinical isolates of gram-positive cocci from Norway

Scandinavian Journal of Infectious Diseases

Volumn 36, Issue 4, 2004, Pages 254-258

  Simonsen, Gunnar S ^a,b   Bergh, Kåre ^c   Bevanger, Lars ^c   Digranes, Asbjørn ^d   Gaustad, Peter ^e   Melby, Kjetil K ^f   Høiby, E Arne ^b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; LINCOMYCIN; LINEZOLID; OXACILLIN; PENICILLIN G; PSEUDOMONIC ACID; RIFAMPICIN; STREPTOMYCIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG MONITORING; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE COCCI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORWAY; PREVALENCE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; SUBSPECIES;

ACETAMIDES; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; MICROBIAL SENSITIVITY TESTS; NORWAY; OXAZOLIDINONES; VIRGINIAMYCIN;

EID: 2642553020     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540410019570     Document Type: Article

References (24)

1. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003; 36: 1433-7.
2. NORM/NORM-VET 2000. Consumption of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Tromsø/Oslo 2002. ISSN:1502-2307.
3. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003; 36: 473-81.
4. Beyer D, Pepper K. The streptogramin antibiotics: updates on their mechanisms of action. Expert Opin Investig Drugs 1998; 7: 591-9.
5. Lina G, Quaglia A, Reverdy ME, Leclercq R, Vandenesch F, Etienne J. Distribution of genes encoding resistance to macrolì des, lincosamides, and streptogramins among staphylococci. Antimicrob Agents Chemother 1999; 43: 1062-6.
6. Malbruny B, Cann A, Bozdogan B, Fantin B, Zarrouk V, Dutka-Malen S, et al. Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46: 2200-7.
7. Kehoe LE, Snidwongse J, Courvalin P, Rafferty JB, Murray IA. Structural basis of synercid (quinupristin-dalfopristin) resistance in Gram-positive bacterial pathogens. J Biol Chem 2003; 278: 29963-70.
8. Leclercq R, Nantas L, Soussy CJ, Duval J. Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolidelincosamide-streptogramin antibiotics. J Antimicrob Chemother 1992; 30 (Suppl A): 67-75.
9. Werner G, Klare I, Witte W. Molecular analysis of streptogramin resistance in enterococci. Int J Med Microbiol 2002; 292: 81-94.
10. Singh KV, Weinstock GM, Murray BE. An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin. Antimicrob Agents Chemother 2002; 46: 1845-50.
11. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839-45.
12. Shinabarger DL, Marotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997; 41: 2132-6.
13. Prystowsky J, Siddiqui F, Chosay J, Shinabarger DL, Millichap J, Peterson LR, Noskin GA. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001; 45: 2154-6.
14. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207-8.
15. Simonsen GS, Småbrekke L, Monnet DL, Sørensen TL, Møller JK, Kristinsson KG, et al. Prevalence of resistance to ampicillin, gentamicin and vancomycin in Enterococcus faecalis and Enterococcus faecium isolates from clinical specimens and use of antimicrobials in 5 Nordic hospitals. J Antimicrob Chemother 2003; 51: 323-31.
16. Andersen BM, Dalen HE, Steinbakk M, Syversen G, Bruun JN, Magnæs B, et al. [Methicillin resistant yellow staphylococci]. Tidsskr Nor Laegeforen 1998; 118: 1182-5. (In Norwegian).
17. Brakstad OG, Mæland JA, Tveten Y. Multiplex polymerase chain reaction for detection of genes for Staphylococcus aureus thermonuclease and methicillin resistance and correlation with oxacillin resistance. APMIS 1993; 101: 681-8.
18. E-test application sheet-EAS008, AB Biodisk, Solna, Sweden.
19. Pedersen MK, Høiby EA, Frøholm LO, Hasseltvedt V, Lermark G, Caugant DA. Systemic pneumococcal disease in Norway 1995-2001: capsular serotypes and antimicrobial resistance. Epidemiol Infect (in press.)
20. Vilhelmsson SE, Tomasz A, Kristinsson KG. Molecular evolution in a multidrug-resistant lineage of Streptococcus pneumoniae: emergence of strains belonging to the serotype 6B Icelandic clone that lost antibiotic resistance traits. J Clin Microbiol 2000; 38: 1375-81.
21. Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A. Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group. J Antimicrob Chemother 2000; 46: 931-40.
22. Ballow CH, Jones RN, Biedenbach DJ. A multicentre evaluation of linezolid antimicrobial activity in North America. Diagn Microbiol Infect Dis 2002; 43: 75-83.
23. Bolmstrom A, Ballow CH, Qwarnstrom A, Biedenbach DJ, Jones RN. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from The Zyvox Antimicrobial Potency Study (ZAPS-Europe). Clin Microbiol Infect 2002; 8: 791-800.
24. Mutnick AH, Biedenbach DJ, Turnidge JD, Jones RN. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis 2002; 43: 65-73.